Xoft surface brachytherapy
This article was originally published in The Gray Sheet
FDA grants 510(k) clearance for a skin and surface treatment applicator for use with Xoft's Axxent electronic brachytherapy system, firm says March 4. Axxent's miniaturized X-ray source allows targeted treatment and limits radiation exposure, Xoft adds. The system was initially cleared in 2005 to treat early-stage breast cancer, and gained clearance in 2008 for all radiation therapy indications, with a specific indication for endometrial and rectal cancers
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.